01 — At a Glance
The King Of Private Healthcare Got A Crown. Now What?
Apollo Hospitals just wrapped Q3 FY26 (nine months to Dec 31, 2025) with consolidated revenue of ₹6,477 crore, PAT of ₹502 crore, and EPS of ₹34.93. Full-year FY26 (Apr ’25 – Mar ’26) net profit stands at ₹1,816 crore with 24.3% return over the past one year. The company declared a ₹10 interim dividend per share. Bed count across India: 8,050 operational (as of Sep 2025). Pharmacy network: 6,928 stores (up from 6,030 last year). CCI approved the pharmacy demerger. CRISIL upgraded the outlook to “Positive” in January 2026. And yes, the stock trades at the highest P/E in the entire healthcare peer set.
- 52-Week High / Low₹8,100 / ₹6,002
- TTM Revenue₹24,215 Cr
- TTM PAT₹1,816 Cr
- Full-Year EPS (FY26 9M)₹34.93
- Operational Beds (Q3)8,050
- Book Value₹632
- Price to Book12.2x
- Dividend Yield0.25%
- Debt / Equity0.88x
- Cash in Bank (Sep ’25)₹3,222 Cr
Context Setter: Apollo Hospitals is consolidating the private healthcare moat — 51 hospitals, 8,050 beds, ₹6,477 crore quarterly revenue, and plans to add 3,600 beds over the next 3 years. The stock has delivered 24.3% annual returns over the past year, but trades at a 61.2x P/E, making it the priciest name in the sector. Meanwhile, they’re demerging the pharmacy and digital businesses into a separate listed entity. Either this is genius compounding, or the market has already priced in that future. Time will tell.
02 — Introduction
Asia’s Hospital King Wants To Multiply Its Kingdoms
Apollo Hospitals isn’t just a hospital company anymore. It’s a vertically integrated healthcare-to-pharma-to-diagnostics empire that’s literally reshaping Indian healthcare one bed, one store, one diagnostic centre at a time.
Founded in 1983 by Dr. Prathap C Reddy, the company pioneered corporate healthcare in India when “hospital” meant government buildings with overworked staff and zero air conditioning. Forty-plus years later, Apollo runs 51 hospitals across India with world-class infrastructure, JCI accreditation, and an ARPOB (Average Revenue Per Occupied Bed) of ₹60,588 per day — among the highest in the sector. The company is now worth ₹1.11 lakh crore in market cap.
But here’s what’s wild: they’re not stopping. Management announced plans to add ~3,600 beds over 3 years, even while the pharmacy and digital businesses (Apollo HealthCo and Apollo Healthtech) are being demerged into a separate publicly listed entity. CRISIL just upgraded to “Positive” outlook. The stock returned 24% in a year. And the P/E is 61.2x. Yes, you read that right.
So what’s really happening? Is this a company in hypergrowth mode, or has the market priced in a future that doesn’t exist yet? Let’s find out — with data, not hopes.
Regulatory Backdrop (Jan 2026): CRISIL upgraded outlook to “Positive” from “Stable.” CCI approved pharmacy demerger on Sep 23, 2025. Stock exchanges gave observation letters in Dec 2025. NCLT hearing initiated. Demerger expected within 15–18 months.
03 — Business Model: How Does A Hospital Empire Actually Work?
Three Legs, One Table, Infinite Headaches.
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
